| 1 |
vitamin K antagonists
(817 times)
|
Vascular Diseases
(201 times)
|
AF (275 times)
NOACs (217 times)
DOACs (165 times)
|
2004 Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX.
|
| 2 |
vitamin K-antagonist anticoagulants
(4 times)
|
Cardiology
(1 time)
|
AF (2 times)
DOACs (2 times)
NOACs (2 times)
|
2015 Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
|
| 3 |
vitamin K oral anticoagulants
(2 times)
|
Medicine
(1 time)
|
DOACs (1 time)
LVT (1 time)
NOACs (1 time)
|
2018 The potential for evaluating the effects of intensified antithrombotic therapy using retinal optical coherence tomography angiography.
|
| 4 |
anti-vitamin K agents
(1 time)
|
Chemistry
(1 time)
|
BMD (1 time)
DOACs (1 time)
LMWHs (1 time)
|
2019 Anticoagulants and Osteoporosis.
|
| 5 |
enoxaparin-vitamin K antagonists
(1 time)
|
Hematology
(1 time)
|
---
|
2016 Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
|
| 6 |
Vit K antagonists
(1 time)
|
Cardiology
(1 time)
|
AF (1 time)
DOACs (1 time)
HHF (1 time)
|
2018 Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
|
| 7 |
vitamin K analogues
(1 time)
|
Health Services
(1 time)
|
CAT (1 time)
DOACs (1 time)
IDPTP (1 time)
|
2017 Advances in managing and preventing thromboembolic disease in cancer patients.
|
| 8 |
vitamin K inhibitors
(1 time)
|
Drug Therapy
(1 time)
|
ADRs (1 time)
DOACs (1 time)
|
2020 What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticogulants and How Can Such Reactions be Prevented?
|
| 9 |
Vitamin K-dependent antagonists
(1 time)
|
Cardiology
(1 time)
|
NOACs (1 time)
|
2016 Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.
|
| 10 |
vitamin K-dependent, drugs interfering with the effects of the vitamin
(1 time)
|
Hematology
(1 time)
|
ACS (1 time)
NOACs (1 time)
TXA2 (1 time)
|
2016 Individualized antithrombotic therapy.
|
A Search Service for Abbreviation / Long Form